New Triple A Polyclonals - Human Protein Atlas release 2023
The Human Protein Atlas releases a new version of its resource each year with expanded data.
October 2023
One of the key components of the Human Protein Atlas project is the use of primary polyclonal antibodies for identifying and locating the proteins of interest.
Atlas Antibodies is the original manufacturer of Triple A Polyclonals which are human anti rabbit polyclonals developed within the Human Protein Atlas project. The antibodies are validated on all major tissues and organs in the human body.The Human Protein Atlas releases a new version of its resource each year with expanded data.
The products listed in the brochure are a selection of TripleA Polyclonals released this year.
Triple A Polyclonal antibodies serve as crucial tools for identifying new biomarkers. They are indispensable in many research fields due to their ability to recognize multiple epitopes on a target protein, ensuring high specificity and sensitivity in detecting disease-related biomarkers.
Their diverse binding sites make them valuable tools for identifying various protein isoforms specific to cancer cells, aiding in precise disease diagnosis and prognosis.
Additionally, polyclonal antibodies offer robustness and versatility, allowing you to explore the heterogeneity of tissues, organs, and cells, leading to a deeper understanding of human biology and the development of targeted therapies for different diseases.
See some of the newly released primary antibodies by the research area.
Cancer: